{"title":"确定双特异性药物管理和肿瘤血液学单位患者随访的护理培训需求：一项非介入性电子调查贝尔研究","authors":"M. Bou, P. Blázquez, J. Parra, M. T. San Miguel","doi":"10.1002/hon.70093_ON06","DOIUrl":null,"url":null,"abstract":"<p>M. Bou, P. Blázquez, J. Parra, and M. T. San Miguel equally contributing author.</p><p><b>Introduction:</b> Advances in the treatment of oncohematological disorders such as non-Hodgkin lymphoma (NHL), driven by new cell therapies targeted with bispecific monoclonal antibodies (mAB), allow for a much more efficient, personalized and selective approach.</p><p>Its high response rate is indisputable, but potential adverse events (AEs) and associated toxicities require a precise monitoring as part of therapeutic management. In this monitoring, the role of the nursing professionals (NP) is fundamental. They actively participate in the management of symptoms, the interpretation of tests, and the advice to patients and families. In order for NPs to be able to effectively manage patients receiving bispecific mAB, it is essential to know what unmet needs are about this therapy in terms of learning, tools and training materials that, from their point of view, would contribute to improving quality and saitsfaction with their work.</p><p>The objective of this research is to identify specific training needs and potential knowledge gaps of NPs related with the management of LNH patients in treatment with bispecific mAb: mechanism of action, monitoring, identification and management of AEs, to establish an adequate care plan.</p><p>This study will provide valuable information on the training needs of oncohematological nursing, which will improve and facilitate the daily work of NPs.</p><p><b>Methods:</b> A cross-sectional observational study will be conducted with approximately 100 hospital NPs, invited to participate by Spanish nursing societies. Data will be collected using an electronic survey. In order to describe the profile of the study population, participants will be asked, about their time of experience as a nurse in oncohematology, as well as in the care of patients with NHL and in the management of bispecific drug therapy, among others.</p><p>To respond to the objective of the study, ad hoc questions have been designed to find out what knowledge/training resources NPs have or consider they would need regarding: (1) general information that allows them to better understand bispecific drug therapy and its mechanism of action; (2) administration and monitoring of bispecific drugs; (3) identification and management of the main AEs related to this therapy. Additionally, three hypothetical clinical cases will be presented to deepen their knowledge on the management of AEs.</p><p>This is a trial in progress. Data collection (fieldwork) is scheduled to take place between April and July 2025. Analysis of the results is expected to be available during the fourth quarter of 2025.</p><p><b>Research</b> <b>funding declaration:</b> This research is funded by Roche Farma S.A.</p><p><b>Keywords:</b> Impact of New Therapies on Patient Care; Education and Training; Symptom Management and Supportive Care</p><p><b>Potential sources of conflict of interest:</b></p><p><b>M. Bou</b></p><p><b>Consultant or advisory role:</b> Roche Farma, S.A.</p><p><b>Honoraria:</b> Roche Farma, S.A.</p><p><b>P. Blázquez</b></p><p><b>Consultant or advisory role:</b> Roche Farma, S.A.</p><p><b>Honoraria:</b> Roche Farma, S.A.</p><p><b>J. Parra</b></p><p><b>Employment or leadership position:</b> Roche Farma, S.A.</p><p><b>M. T. San Miguel</b></p><p><b>Consultant or advisory role:</b> Roche Farma, S.A.</p><p><b>Honoraria:</b> Roche Farma, S.A.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 S3","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70093_ON06","citationCount":"0","resultStr":"{\"title\":\"IDENTIFYING NURSING TRAINING NEEDS FOR THE MANAGEMENT OF BISPECIFIC DRUGS AND PATIENT FOLLOW-UP IN ONCO-HEMATOLOGY UNITS: A NON-INTERVENTIONAL, E-SURVEY BELL STUDY\",\"authors\":\"M. Bou, P. Blázquez, J. Parra, M. T. San Miguel\",\"doi\":\"10.1002/hon.70093_ON06\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>M. Bou, P. Blázquez, J. Parra, and M. T. San Miguel equally contributing author.</p><p><b>Introduction:</b> Advances in the treatment of oncohematological disorders such as non-Hodgkin lymphoma (NHL), driven by new cell therapies targeted with bispecific monoclonal antibodies (mAB), allow for a much more efficient, personalized and selective approach.</p><p>Its high response rate is indisputable, but potential adverse events (AEs) and associated toxicities require a precise monitoring as part of therapeutic management. In this monitoring, the role of the nursing professionals (NP) is fundamental. They actively participate in the management of symptoms, the interpretation of tests, and the advice to patients and families. In order for NPs to be able to effectively manage patients receiving bispecific mAB, it is essential to know what unmet needs are about this therapy in terms of learning, tools and training materials that, from their point of view, would contribute to improving quality and saitsfaction with their work.</p><p>The objective of this research is to identify specific training needs and potential knowledge gaps of NPs related with the management of LNH patients in treatment with bispecific mAb: mechanism of action, monitoring, identification and management of AEs, to establish an adequate care plan.</p><p>This study will provide valuable information on the training needs of oncohematological nursing, which will improve and facilitate the daily work of NPs.</p><p><b>Methods:</b> A cross-sectional observational study will be conducted with approximately 100 hospital NPs, invited to participate by Spanish nursing societies. Data will be collected using an electronic survey. In order to describe the profile of the study population, participants will be asked, about their time of experience as a nurse in oncohematology, as well as in the care of patients with NHL and in the management of bispecific drug therapy, among others.</p><p>To respond to the objective of the study, ad hoc questions have been designed to find out what knowledge/training resources NPs have or consider they would need regarding: (1) general information that allows them to better understand bispecific drug therapy and its mechanism of action; (2) administration and monitoring of bispecific drugs; (3) identification and management of the main AEs related to this therapy. Additionally, three hypothetical clinical cases will be presented to deepen their knowledge on the management of AEs.</p><p>This is a trial in progress. Data collection (fieldwork) is scheduled to take place between April and July 2025. Analysis of the results is expected to be available during the fourth quarter of 2025.</p><p><b>Research</b> <b>funding declaration:</b> This research is funded by Roche Farma S.A.</p><p><b>Keywords:</b> Impact of New Therapies on Patient Care; Education and Training; Symptom Management and Supportive Care</p><p><b>Potential sources of conflict of interest:</b></p><p><b>M. Bou</b></p><p><b>Consultant or advisory role:</b> Roche Farma, S.A.</p><p><b>Honoraria:</b> Roche Farma, S.A.</p><p><b>P. Blázquez</b></p><p><b>Consultant or advisory role:</b> Roche Farma, S.A.</p><p><b>Honoraria:</b> Roche Farma, S.A.</p><p><b>J. Parra</b></p><p><b>Employment or leadership position:</b> Roche Farma, S.A.</p><p><b>M. T. San Miguel</b></p><p><b>Consultant or advisory role:</b> Roche Farma, S.A.</p><p><b>Honoraria:</b> Roche Farma, S.A.</p>\",\"PeriodicalId\":12882,\"journal\":{\"name\":\"Hematological Oncology\",\"volume\":\"43 S3\",\"pages\":\"\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-06-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70093_ON06\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematological Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/hon.70093_ON06\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematological Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hon.70093_ON06","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
M. Bou， P. Blázquez， J. Parra，和M. T. San Miguel。导语：在以双特异性单克隆抗体（mAB）为靶点的新细胞疗法的推动下，肿瘤血液系统疾病（如非霍奇金淋巴瘤（NHL））的治疗取得了进展，从而实现了更高效、个性化和选择性的治疗方法。它的高反应率是无可争议的，但潜在的不良事件（ae）和相关的毒性需要作为治疗管理的一部分进行精确监测。在这种监测中，护理专业人员（NP）的作用是基本的。他们积极参与症状管理，解释检查结果，并向患者和家属提供建议。为了使NPs能够有效地管理接受双特异性单克隆抗体治疗的患者，了解这种治疗在学习、工具和培训材料方面的未满足需求是至关重要的，从他们的角度来看，这将有助于提高他们的工作质量和满意度。本研究的目的是确定与LNH患者双特异性单抗治疗管理相关的NPs的特定培训需求和潜在知识缺口：ae的作用机制、监测、识别和管理，以建立适当的护理计划。本研究将为肿瘤血液学护理培训需求提供有价值的信息，以改善和促进NPs的日常工作。方法：一项横断面观察性研究将由西班牙护理学会邀请的大约100家医院NPs进行。数据将采用电子调查方式收集。为了描述研究人群的概况，参与者将被问及他们作为肿瘤血液学护士的经验，以及在NHL患者护理和双特异性药物治疗管理等方面的经验。为了回应研究的目的，我们设计了一些特别的问题，以了解NPs拥有或认为他们需要哪些知识/培训资源：(1)使他们能够更好地理解双特异性药物治疗及其作用机制的一般信息；(2)双特异性药物的给药和监测；(3)鉴别和处理与该疗法相关的主要不良事件。此外，将介绍三个假设的临床病例，以加深他们对ae管理的了解。这是一项正在进行的试验。数据收集（实地调查）计划在2025年4月至7月之间进行。对结果的分析预计将在2025年第四季度公布。研究经费声明：本研究由Roche Farma s.a.资助。关键词：新疗法对患者护理的影响；教育和培训；症状管理和支持性护理潜在的利益冲突来源：M。顾问或顾问角色：Roche Farma， s.a.o honaria: Roche Farma, s.a.p BlázquezConsultant或顾问角色：Roche Farma， s.a.o honaria: Roche Farma, s.a.j parra就业或领导职位：Roche Farma， S.A.M. T. San miguel顾问或顾问角色：Roche Farma， s.a.o honaria: Roche Farma, s.a.p arraa
IDENTIFYING NURSING TRAINING NEEDS FOR THE MANAGEMENT OF BISPECIFIC DRUGS AND PATIENT FOLLOW-UP IN ONCO-HEMATOLOGY UNITS: A NON-INTERVENTIONAL, E-SURVEY BELL STUDY
M. Bou, P. Blázquez, J. Parra, and M. T. San Miguel equally contributing author.
Introduction: Advances in the treatment of oncohematological disorders such as non-Hodgkin lymphoma (NHL), driven by new cell therapies targeted with bispecific monoclonal antibodies (mAB), allow for a much more efficient, personalized and selective approach.
Its high response rate is indisputable, but potential adverse events (AEs) and associated toxicities require a precise monitoring as part of therapeutic management. In this monitoring, the role of the nursing professionals (NP) is fundamental. They actively participate in the management of symptoms, the interpretation of tests, and the advice to patients and families. In order for NPs to be able to effectively manage patients receiving bispecific mAB, it is essential to know what unmet needs are about this therapy in terms of learning, tools and training materials that, from their point of view, would contribute to improving quality and saitsfaction with their work.
The objective of this research is to identify specific training needs and potential knowledge gaps of NPs related with the management of LNH patients in treatment with bispecific mAb: mechanism of action, monitoring, identification and management of AEs, to establish an adequate care plan.
This study will provide valuable information on the training needs of oncohematological nursing, which will improve and facilitate the daily work of NPs.
Methods: A cross-sectional observational study will be conducted with approximately 100 hospital NPs, invited to participate by Spanish nursing societies. Data will be collected using an electronic survey. In order to describe the profile of the study population, participants will be asked, about their time of experience as a nurse in oncohematology, as well as in the care of patients with NHL and in the management of bispecific drug therapy, among others.
To respond to the objective of the study, ad hoc questions have been designed to find out what knowledge/training resources NPs have or consider they would need regarding: (1) general information that allows them to better understand bispecific drug therapy and its mechanism of action; (2) administration and monitoring of bispecific drugs; (3) identification and management of the main AEs related to this therapy. Additionally, three hypothetical clinical cases will be presented to deepen their knowledge on the management of AEs.
This is a trial in progress. Data collection (fieldwork) is scheduled to take place between April and July 2025. Analysis of the results is expected to be available during the fourth quarter of 2025.
Researchfunding declaration: This research is funded by Roche Farma S.A.
Keywords: Impact of New Therapies on Patient Care; Education and Training; Symptom Management and Supportive Care
Potential sources of conflict of interest:
M. Bou
Consultant or advisory role: Roche Farma, S.A.
Honoraria: Roche Farma, S.A.
P. Blázquez
Consultant or advisory role: Roche Farma, S.A.
Honoraria: Roche Farma, S.A.
J. Parra
Employment or leadership position: Roche Farma, S.A.
期刊介绍：
Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged:
-Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders
-Diagnostic investigations, including imaging and laboratory assays
-Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases
-Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies
-Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems.
Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
